Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma

Science Translational Medicine

Volumn 7, Issue 282, 2015, Pages

  Bruns, Heiko ^a   Büttner, Maike ^a   Fabri, Mario ^b   Mougiakakos, Dimitrios ^a   Bittenbring, Jörg T ^c   Hoffmann, Markus H ^a   Beier, Fabian ^d   Pasemann, Shirin ^a   Jitschin, Regina ^a   Hofmann, Andreas D ^a   Neumann, Frank ^c   Daniel, Christoph ^a   Maurberger, Anna ^a   Kempkes, Bettina ^e   Amann, Kerstin ^a   Mackensen, Andreas ^a   Gerbitz, Armin ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CATHELICIDIN; RITUXIMAB; VITAMIN D; 25-HYDROXYVITAMIN D; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B CELL LYMPHOMA CELL; CANCER GRADING; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MACROPHAGE; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; TUMOR ASSOCIATED LEUKOCYTE; VITAMIN METABOLISM; ANALOGS AND DERIVATIVES; CELL DEATH; DRUG EFFECTS; METABOLISM; MITOCHONDRION; PATHOLOGY;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIMICROBIAL CATIONIC PEPTIDES; CELL DEATH; CELL PROLIFERATION; HUMANS; LYMPHOMA, B-CELL; MACROPHAGES; MITOCHONDRIA; VITAMIN D;

EID: 84927587443     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa3230     Document Type: Article

References (50)

1. J. W. Pollard, Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71-78 (2004).
2. G. L. Beatty, E. G. Chiorean, M. P. Fishman, B. Saboury, U. R. Teitelbaum, W. Sun, R. D. Huhn, W. Song, D. Li, L. L. Sharp, D. A. Torigian, P. J. O'Dwyer, R. H. Vonderheide, CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011).
3. S. Jaiswal, M. P. Chao, R. Majeti, I. L. Weissman, Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 31, 212-219 (2010).
4. J. Uchida, Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, T. F. Tedder, The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor- dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659-1669 (2004).
5. N. Gül, L. Babes, K. Siegmund, R. Korthouwer, M. Bögels, R. Braster, G. Vidarsson, T. L. ten Hagen, P. Kubes, M. van Egmond, Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Invest. 124, 812-823 (2014).
6. T. Keler, P. K. Wallace, L. A. Vitale, C. Russoniello, K. Sundarapandiyan, R. F. Graziano, Y. M. Deo, Differential effect of cytokine treatment on Fca receptor I- And Fcg receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages. J. Immunol. 164, 5746-5752 (2000).
7. M. R. Dinapoli, C. L. Calderon, D. M. Lopez, The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J. Exp. Med. 183, 1323-1329 (1996).
8. A. Sica, T. Schioppa, A. Mantovani, P. Allavena, Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anticancer therapy. Eur. J. Cancer 42, 717-727 (2006).
9. P. Sinha, V. K. Clements, S. Ostrand-Rosenberg, Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65, 11743-11751 (2005).
10. M. Chittezhath, M. K. Dhillon, J. Y. Lim, D. Laoui, I. N. Shalova, Y. L. Teo, J. Chen, R. Kamaraj, L. Raman, J. Lum, T. P. Thamboo, E. Chiong, F. Zolezzi, H. Yang, J. A. Van Ginderachter, M. Poidinger, A. S. Wong, S. K. Biswas, Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity 41, 815-829 (2014).
11. P. T. Liu, S. Stenger, H. Li, L. Wenzel, B. H. Tan, S. R. Krutzik, M. T. Ochoa, J. Schauber, K. Wu, C.Meinken, D. L. Kamen, M.Wagner, R. Bals, A. Steinmeyer, U. Zügel, R. L. Gallo, D. Eisenberg, M. Hewison, B. W. Hollis, J. S. Adams, B. R. Bloom, R. L. Modlin, Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770-1773 (2006).
12. M. Fabri, S. Stenger, D. M. Shin, J. M. Yuk, P. T. Liu, S. Realegeno, H. M. Lee, S. R. Krutzik, M. Schenk, P. A. Sieling, R. Teles, D. Montoya, S. S. Iyer, H. Bruns, D. M. Lewinsohn, B. W. Hollis, M. Hewison, J. S. Adams, A. Steinmeyer, U. Zügel, G. Cheng, E. K. Jo, B. R. Bloom, R. L. Modlin, Vitamin D is required for IFN-g-mediated antimicrobial activity of human macrophages. Sci. Transl. Med. 3, 104ra102 (2011).
13. H. Xu, A. Soruri, R. K. Gieseler, J. H. Peters, 1, 25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand. J. Immunol. 38, 535-540 (1993).
14. M. S. Cohen, D. E. Mesler, R. G. Snipes, T. K. Gray, 1, 25-Dihydroxyvitamin D3 activates secretion of hydrogen peroxide by human monocytes. J. Immunol. 136, 1049-1053 (1986).
15. A. F. Gombart, N. Borregaard, H. P. Koeffler, Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1, 25-dihydroxyvitamin D3. FASEB J. 19, 1067-1077 (2005).
16. M. Zanetti, Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75, 39-48 (2004).
17. A. S. Büchau, S. Morizane, J. Trowbridge, J. Schauber, P. Kotol, J. D. Bui, R. L. Gallo, The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J. Immunol. 184, 369-378 (2010).
18. M. T. Drake, M. J. Maurer, B. K. Link, T. M. Habermann, S. M. Ansell, I. N. Micallef, J. L. Kelly, W. R. Macon, G. S. Nowakowski, D. J. Inwards, P. B. Johnston, R. J. Singh, C. Allmer, S. L. Slager, G. J. Weiner, T. E. Witzig, J. R. Cerhan, Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J. Clin. Oncol. 28, 4191-4198 (2010).
19. J. T. Bittenbring, F. Neumann, B. Altmann, M. Achenbach, J. Reichrath, M. Ziepert, J. Geisel, E. Regitz, G. Held, M. Pfreundschuh, Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J. Clin. Oncol. 32, 3242-3248 (2014).
20. N. Lopes, B. Sousa, D. Martins, M. Gomes, D. Vieira, L. A. Veronese, F. Milanezi, J. Paredes, J. L. Costa, F. Schmitt, Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: A study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10, 483 (2010).
21. D. Montoya, D. Cruz, R. M. Teles, D. J. Lee, M. T. Ochoa, S. R. Krutzik, R. Chun, M. Schenk, X. Zhang, B. G. Ferguson, A. E. Burdick, E. N. Sarno, T. H. Rea, M. Hewison, J. S. Adams, G. Cheng, R. L. Modlin, Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe 6, 343-353 (2009).
22. C. A. Ogden, J. D. Pound, B. K. Batth, S. Owens, I. Johannessen, K. Wood, C. D. Gregory, Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10- Activated macrophages: Implications for Burkitt's lymphoma. J. Immunol. 174, 3015-3023 (2005).
23. A. C. Ross, J. E. Manson, S. A. Abrams, J. F. Aloia, P. M. Brannon, S. K. Clinton, R. A. Durazo-Arvizu, J. C. Gallagher, R. L. Gallo, G. Jones, C. S. Kovacs, S. T. Mayne, C. J. Rosen, S. A. Shapses, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J. Clin. Endocrinol. Metab. 96, 53-58 (2011).
24. J. Xue, S. V. Schmidt, J. Sander, A. Draffehn, W. Krebs, I. Quester, D. De Nardo, T. D. Gohel, M. Emde, L. Schmidleithner, H. Ganesan, A. Nino-Castro, M. R. Mallmann, L. Labzin, H. Theis, M. Kraut, M. Beyer, E. Latz, T. C. Freeman, T. Ulas, J. L. Schultze, Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40, 274-288 (2014).
25. J. Hasenkamp, A. Borgerding, G. Wulf, M Uhrberg, W. Jung, S. Dingeldein, L. Truemper, B. Glass, Resistance against natural killer cell cytotoxicity: Analysis of mechanisms. Scand. J. Immunol. 64, 444-449 (2006).
26. C. A. Alvarez-Breckenridge, J. Yu, R. Price, J. Wojton, J. Pradarelli, H. Mao, M. Wei, Y. Wang, S. He, J. Hardcastle, S. A. Fernandez, B. Kaur, S. E. Lawler, E. Vivier, O. Mandelboim, A. Moretta, M. A. Caligiuri, E. A. Chiocca, NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat. Med. 18, 1827-1834 (2012).
27. O. E. Sørensen, P. Follin, A. H. Johnsen, J. Calafat, G. S. Tjabringa, P. S. Hiemstra, N. Borregaard, Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97, 3951-3959 (2001).
28. Z. Oren, J. C. Lerman, G. H. Gudmundsson, B. Agerberth, Y. Shai, Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: Relevance to the molecular basis for its non-cell-selective activity. Biochem. J. 341 (Pt. 3), 501-513 (1999).
29. K. A. Sochacki, K. J. Barns, R. Bucki, J. C. Weisshaar, Real-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37. Proc. Natl. Acad. Sci. U.S.A. 108, E77-E81 (2011).
30. M. Schuhmacher, M. S. Staege, A. Pajic, A. Polack, U. H. Weidle, G. W. Bornkamm, D. Eick, F. Kohlhuber, Control of cell growth by c-Myc in the absence of cell division. Curr. Biol. 9, 1255-1288 (1999).
31. S. B. Coffelt, F. C. Marini, K. Watson, K. J. Zwezdaryk, J. L. Dembinski, H. L. LaMarca, S. L. Tomchuck, K. Honer zu Bentrup, E. S. Danka, S. L. Henkle, A. B. Scandurro, The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc. Natl. Acad. Sci. U.S.A. 106, 3806-3811 (2009).
32. S. M. Ansell, M. Stenson, T. M. Habermann, D. F. Jelinek, T. E. Witzig, Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J. Clin. Oncol. 19, 720-726 (2001).
33. A. Risso, M. Zanetti, R. Gennaro, Cytotoxicity and apoptosis mediated by two peptides of innate immunity. Cell. Immunol. 189, 107-115 (1998).
34. J. B. McPhee, R. E. Hancock, Function and therapeutic potential of host defence peptides. J. Pept. Sci. 11, 677-687 (2005).
35. M. Klähn, M. Zacharias, Transformations in plasma membranes of cancerous cells and resulting consequences for cation insertion studied with molecular dynamics. Phys. Chem. Chem. Phys. 15, 14427-14441 (2013).
36. F. Weinberg, N. S. Chandel, Mitochondrial metabolism and cancer. Ann. N. Y. Acad. Sci. 1177, 66-73 (2009).
37. P. Farinha, H. Masoudi, B. F. Skinnider, K. Shumansky, J. J. Spinelli, K. Gill, R. Klasa, N. Voss, J. M. Connors, R. D. Gascoyne, Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106, 2169-2174 (2005).
38. M. P. Purdue, Q. Lan, A. Kricker, C.M. Vajdic, N. Rothman, B. K. Armstrong, Vitamin D receptor gene polymorphisms and risk of non-Hodgkin's lymphoma. Haematologica 92, 1145-1146 (2007).
39. C. Esteban, M. Geuskens, J. M. Ena, Z. Mishal, A. Macho, J. M. Torres, J. Uriel, Receptormediated uptake and processing of vitamin D-binding protein in human B-lymphoid cells. J. Biol. Chem. 267, 10177-10183 (1992).
40. G. M. Klug-Micu, S. Stenger, A. Sommer, P. T. Liu, S. R. Krutzik, R. L. Modlin, M. Fabri, CD40 ligand and interferon-g induce an antimicrobial response against Mycobacterium tuberculosis in human monocytes. Immunology 139, 121-128 (2013).
41. K. Pryor, J. Goddard, D. Goldstein, P. Stricker, P. Russell, D. Golovsky, R. Penny, Bacillus Calmette-Guerin (BCG) enhances monocyte- And lymphocyte-mediated bladder tumour cell killing. Br. J. Cancer 71, 801-807 (1995).
42. P. A. Meyers, C. L. Schwartz, M. D. Krailo, J. H. Healey, M. L. Bernstein, D. Betcher, W. S. Ferguson, M. C. Gebhardt, A. M. Goorin, M. Harris, E. Kleinerman, M. P. Link, H. Nadel, M. Nieder, G. P. Siegal, M. A. Weiner, R. J.Wells, R. B. Womer, H. E. Grier; Children's Oncology Group, Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-A report from the Children's Oncology Group. J. Clin. Oncol. 26, 633-638 (2008).
43. A. Morales, D. Eidinger, A. W. Bruce, Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116, 180-183 (1976).
44. D. Morton, F. R. Eilber, R. A. Malmgren, W. C. Wood, Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68, 158-163 (1970).
45. G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, H. Watier, Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99, 754-758 (2002).
46. M. Taskinen, M. L. Karjalainen-Lindsberg, H. Nyman, L. M. Eerola, S. Leppa, A high tumorassociated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin. Cancer Res. 13, 5784-5789 (2007).
47. D. Canioni, G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchhauser, T. Lamy, A. Sonet, M. C. Rousselet, C. Foussard, L. Xerri, High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J. Clin. Oncol. 26, 440-446 (2008).
48. J. T. Bittenbring, B. Altmann, F. Neumann, M. Achenbach, J. Reichrath, M. Ziepert, J. Geisel, E. Regitz, G. Held, M. Pfreundschuh, 25-OH-vitamin-D deficiency impairs rituximab-mediated cellular cytotoxicity and is associated with an inferior outcome of elderly DLBCL patients treated with rituximab. Blood 122, 1819 (2013).
49. M. P. Chao, A. A. Alizadeh, C. Tang, J. H. Myklebust, B. Varghese, S. Gill, M. Jan, A. C. Cha, C. K. Chan, B. T. Tan, C. Y. Park, F. Zhao, H. E. Kohrt, R. Malumbres, J. Briones, R. D. Gascoyne, I. S. Lossos, R. Levy, I. L. Weissman, R. Majeti, Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699-713 (2010).
50. K. Bohmann, G. Hennig, U. Rogel, C. Poremba, B. M. Mueller, P. Fritz, S. Stoerkel, K. L. Schaefer, RNA extraction from archival formalin-fixed paraffin-embedded tissue: A comparison of manual, semiautomated, and fully automated purification methods. Clin. Chem. 55, 1719-1727 (2009).